Jazz Pharmaceuticals Reports Q3 Financial Results, Raises Full-Year Earnings Guidance

Jazz Pharmaceuticals plc (NASDAQ: JAZZ), a global biopharmaceutical company, announced its financial results Tuesday afternoon for the third quarter of 2021 and updated financial guidance for 2021.

  •  

"Last year, we set the ambitious corporate objective of completing five key commercial launches through and 2021. With the launch of Xywav for idiopathic hypersomnia earlier this month, we have now accomplished this goal, demonstrating our significant execution capabilities and commitment to bring important new medicines forward for patients," Bruce Cozadd, chairman, and CEO of Jazz Pharmaceuticals said late Tuesday in a press release.

Financial Highlights:

  • GAAP net income (loss) for 3Q21 was ($52.8 million), or ($0.86) per diluted share, compared to $148.2 million, or $2.64 per diluted share, for 3Q20.
  • Non-GAAP adjusted net income for 3Q21 was $261.4 million, or $4.20 per diluted share, compared to $242.1 million, or $4.31 per diluted share, for 3Q20.

Cash Flow and Balance Sheet:

As of September …

Full story available on Benzinga.com

More Jazz Pharmaceuticals Reports Q3 Financial Results, Raises Full-Year Earnings Guidance